BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary

BioCryst Pharmaceuticals

05/08/2026 14:31

BioCryst Pharmaceuticals, Inc. BCRX.OQ reported quarterly adjusted earnings of 30 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 4 cents.  The mean expectation of ten analysts for the quarter was for earnings of 12 cents per share. Wall Street expected results to range from -5 cents to 31 cents per share.
Revenue rose 33.6% to $218.25 million from a year ago; analysts expected $182.51 million. 
BioCryst Pharmaceuticals, Inc.'s reported EPS for the quarter was 30 cents​.
The company reported quarterly net income of $78.4 million.
BioCryst Pharmaceuticals, Inc. shares had fallen by 9.8% this quarter and gained 15.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 10.7% in the last three months.​ 
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." 
This summary was machine generated from LSEG data August 5 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.12
0.30
Beat
Mar. 31 2026 
0.05
-0.09
Missed
Dec. 31 2025 
0.04
0.01
Missed
Sep. 30 2025 
0.04
0.06
Beat